JP2015509368A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509368A5
JP2015509368A5 JP2014558920A JP2014558920A JP2015509368A5 JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5 JP 2014558920 A JP2014558920 A JP 2014558920A JP 2014558920 A JP2014558920 A JP 2014558920A JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014558920A
Other languages
English (en)
Japanese (ja)
Other versions
JP6101715B2 (ja
JP2015509368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/027580 external-priority patent/WO2013130381A1/en
Publication of JP2015509368A publication Critical patent/JP2015509368A/ja
Publication of JP2015509368A5 publication Critical patent/JP2015509368A5/ja
Application granted granted Critical
Publication of JP6101715B2 publication Critical patent/JP6101715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014558920A 2012-02-27 2013-02-25 Cx3cr1結合ポリペプチド Active JP6101715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261603622P 2012-02-27 2012-02-27
US61/603,622 2012-02-27
PCT/US2013/027580 WO2013130381A1 (en) 2012-02-27 2013-02-25 Cx3cr1-binding polypeptides

Publications (3)

Publication Number Publication Date
JP2015509368A JP2015509368A (ja) 2015-03-30
JP2015509368A5 true JP2015509368A5 (enExample) 2015-05-07
JP6101715B2 JP6101715B2 (ja) 2017-03-22

Family

ID=47884535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558920A Active JP6101715B2 (ja) 2012-02-27 2013-02-25 Cx3cr1結合ポリペプチド

Country Status (27)

Country Link
US (6) US9035029B2 (enExample)
EP (2) EP2820046B1 (enExample)
JP (1) JP6101715B2 (enExample)
KR (1) KR102008136B1 (enExample)
CN (3) CN108610421B (enExample)
AP (1) AP2014007791A0 (enExample)
AR (1) AR090158A1 (enExample)
AU (1) AU2013226340B2 (enExample)
CA (1) CA2862182A1 (enExample)
CL (1) CL2014002072A1 (enExample)
EA (1) EA028183B1 (enExample)
EC (1) ECSP14020402A (enExample)
GE (1) GEP201706773B (enExample)
IL (3) IL291571B2 (enExample)
IN (1) IN2014DN05756A (enExample)
MD (1) MD4548C1 (enExample)
MX (1) MX349192B (enExample)
NZ (1) NZ627260A (enExample)
PE (1) PE20141859A1 (enExample)
PH (2) PH12021553014A1 (enExample)
SG (1) SG11201405283SA (enExample)
TN (1) TN2014000360A1 (enExample)
TW (1) TWI598361B (enExample)
UA (1) UA115781C2 (enExample)
UY (1) UY34644A (enExample)
WO (1) WO2013130381A1 (enExample)
ZA (3) ZA201405021B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
CN108610421B (zh) 2012-02-27 2022-08-19 阿布林克斯有限公司 Cx3cr1结合多肽
US9637542B2 (en) * 2013-08-21 2017-05-02 Boehringer Ingelheim International Gmbh CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
EP3325512B1 (en) 2015-07-23 2023-09-06 Inhibrx, Inc. Multivalent and multispecific gitr-binding fusion proteins
JP7328761B2 (ja) 2016-01-11 2023-08-17 インヒブルクス インコーポレイテッド 多価多重特異性ox40結合融合タンパク質
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
AU2017229687A1 (en) * 2016-03-08 2018-09-20 Takeda Pharmaceutical Company Limited Inducible binding proteins and methods of use
EA201991269A1 (ru) * 2016-11-29 2019-10-31 Профилактический агент, агент, подавляющий начало заболевания, или терапевтический агент для прогрессирующих иммунных демиелинизирующих заболеваний
US20190367623A1 (en) * 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
AU2019321490B2 (en) 2018-08-13 2025-09-04 Inhibrx Biosciences, Inc. Ox40-binding polypeptides and uses thereof
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN110675421B (zh) * 2019-08-30 2022-03-15 电子科技大学 基于少量标注框的深度图像协同分割方法
EP4157883A4 (en) * 2020-06-02 2024-12-04 Children's Medical Center Corporation NANOBODY CONJUGATES (VHH) AND THEIR USES
WO2022165434A2 (en) * 2021-02-01 2022-08-04 The General Hospital Corporation Fc-enhanced antibodies for prevention and treatment of ebola virus infection
TW202246334A (zh) * 2021-02-02 2022-12-01 美商美國禮來大藥廠 Gitr拮抗劑及其使用方法
WO2024017915A1 (en) 2022-07-18 2024-01-25 Ablynx N.V. Cx3cr1-binding compounds, uses thereof and related methods
JPWO2024135794A1 (enExample) 2022-12-22 2024-06-27
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
AU2000273378A1 (en) * 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
JP4123856B2 (ja) 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003243532A1 (en) 2002-06-10 2003-12-22 Metabolex, Inc. Methods of treating and diagnosing diabetes with cx3cr1 modulators
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
WO2005103684A2 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
CA2615460A1 (en) 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20100113339A1 (en) * 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン.ヴェー. 血清タンパク質と結合可能なペプチド
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
WO2010070394A1 (en) 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
WO2011044377A2 (en) 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
EP2486056A1 (en) * 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
EP2648754A4 (en) * 2010-12-07 2016-02-24 Philadelphia Health & Educatio METHOD OF INHIBITING CANCER METASTASES
CN108610421B (zh) 2012-02-27 2022-08-19 阿布林克斯有限公司 Cx3cr1结合多肽
US9637542B2 (en) 2013-08-21 2017-05-02 Boehringer Ingelheim International Gmbh CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease

Similar Documents

Publication Publication Date Title
JP2014026276A5 (enExample)
JP2014026274A5 (enExample)
JP2014026275A5 (enExample)
JP2015511482A5 (enExample)
JP2015508051A5 (enExample)
JP2013212124A5 (enExample)
JP2014189812A5 (enExample)
JP2015178437A5 (enExample)
JP2013241444A5 (enExample)
JP2014503786A5 (enExample)
JP2015107586A5 (enExample)
JP2014220238A5 (enExample)
JP2015500269A5 (enExample)
JP2015077594A5 (enExample)
JP2016075837A5 (enExample)
JP2015518513A5 (enExample)
JP2015007765A5 (enExample)
JP2016505534A5 (enExample)
JP2014520787A5 (enExample)
JP2015143316A5 (enExample)
JP2015131953A5 (enExample)
JP2014534151A5 (enExample)
JP2014520786A5 (enExample)
JP2015160926A5 (enExample)
JP2016103417A5 (enExample)